Page last updated: 2024-10-15

nartograstim

Description

nartograstim: a mutein of recombinant human G-CSF [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID156963546
MeSH IDM0195526

Synonyms (1)

Synonym
nartograstim

Research Excerpts

Overview

Nartograstim is a recombinant variant of human G-CSF.

ExcerptReference
"Nartograstim is a recombinant variant of human G-CSF."( Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium.
Barazzone, GC; Borelli, P; Carvalho, E; Eguia, FAP; Gonçalves, VM; Ho, PL; Lieberman, C; Makiyama, E; Mascarelli, DE; Rodríguez, GR, 2021
)

Effects

ExcerptReference
"Nartograstim has been produced in Escherichia coli as inclusion bodies (IB) and presents higher stability and biological activity than the wild type of human G-CSF because of its mutations."( Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium.
Barazzone, GC; Borelli, P; Carvalho, E; Eguia, FAP; Gonçalves, VM; Ho, PL; Lieberman, C; Makiyama, E; Mascarelli, DE; Rodríguez, GR, 2021
)

Pharmacokinetics

ExcerptReference
" The plasma concentration-time profiles of NTG in rats and monkeys were analyzed by nonlinear pharmacokinetic models which contained both linear and Michaelis-Menten type elimination from the central compartment."( Nonlinear pharmacokinetics of a recombinant human granulocyte colony-stimulating factor derivative (nartograstim): species differences among rats, monkeys and humans.
Kato, Y; Kobayashi, S; Kuwabara, T; Sugiyama, Y; Suzuki, H, 1994
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's24 (63.16)18.2507
2000's11 (28.95)29.6817
2010's2 (5.26)24.3611
2020's1 (2.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (13.16%)5.53%
Reviews1 (2.63%)6.00%
Case Studies2 (5.26%)4.05%
Observational0 (0.00%)0.25%
Other30 (78.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]